Tue. 7 May 2024, 6:02am ET
Benzinga
Earnings, Earnings Beats, News
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.05 by 580 percent. This is a 143.04 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $137.74 million which beat the analyst consensus estimate of $84.51 million by 62.98 percent. This is a 466.14 percent increase over sales of $24.33 million the same period last year.